OMICS Journals are welcoming Submissions

OMICS International welcomes submissions that are original and technically sound so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: http://omicsonline.org/Submitmanuscript.php



Fazlul H Sarkar

Professor Pancreatic Disorders & Therapy



Dr. Sarkar is currently a Distinguished Professor, Departments of Pathology and Oncology at Karmanos Cancer Institute, Wayne State University School of Medicine. Dr. Sarkar's early research, which still continues, is focused on understanding the role of a "master" transcription factor and the regulation of its upstream and downstream signaling molecules in solid tumors, and focusing on tumor microenvironment. Moreover, his research has been directed toward elucidating the molecular mechanism(s) of action of "natural agents", focusing on the regulation of miRNA and their target genes for cancer prevention and therapy.

The discoveries from in vitro and in vivo preclinical studies led to the design and execution of multiple Phase I/II clinical trials in breast, pancreas and prostate cancer for assessing the effects of several "natural agents" in the alterations of biomarkers as well as some early clinical efficacy testing. Dr. Sarkar's research led to the concept of chemo-sensitization of cancer cells by reversing their drug-resistance phenotype to conventional therapeutics (chemo-radio-therapy), and all of which has been focused on tumor microenvironment, and provided rationale for clinical trials conducted at the Karmanos Cancer Institute. The innovation of his basic science research has attracted clinicians to collaborate with him, which clearly documents his leadership in translational research.

*Research Interests


- Cancer biology
- Cancer drug discovery
- Experimental therapeutics
- > Medicinal chemistry
- Molecular mechanism of tumor aggressiveness with focus on tumor microenvironment
- > Pre-clinical model research and conducting clinical trials

Recent Publications

- Pharmacological Intervention through Dietary Nutraceuticals in Gastrointestinal Neoplasia.
- Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.
- Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.

Cancer biology

- *Derived from Greek word for crab, karkinoma
- *Malignant tumor are ambitious. They have two
- *goals in life: to survive and to conquer new territory metastasizing
- *A class of genetic diseases, in that aberration of key genetic and resultant molecular pathways are critical for carcinogenesis. Cancer is not a single disease, but many with related features
- *Such key events have been called hallmarks of cancer.
- *There is also increasing evidence for a major role of epigenetic aberrations in cancers



Related journals

- > Journal of the Pancreas
- Journal of Gastrointestinal & Digestive System





Thank You

Signature of the editor

Approved and Signed by Dr. Sarkar